Quest Diagnostics, Celera eye April 13 timeline for U.S. merger review
Antitrust regulators are expected to decide by April 13 whether to further investigate Quest Diagnostics’ acquisition of Celera, a provider of molecular diagnostic products.Antitrust regulators are expected to decide by April...To view the full article, register now.
Already a subscriber? Click here to view full article